Comparative Pharmacology
Head-to-head clinical analysis: BUSULFEX versus EVOMELA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUSULFEX versus EVOMELA.
BUSULFEX vs EVOMELA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Busulfan is a bifunctional alkylating agent that cross-links DNA, leading to inhibition of DNA replication and cell death.
EVOMELA (melphalan) is a bifunctional alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription, leading to cell death.
Busulfan 0.8 mg/kg IV every 6 hours for 4 days (total 16 doses) or 3.2 mg/kg IV once daily for 4 days, based on ideal body weight or actual body weight (whichever is lower).
140-200 mg/m² IV over 30 minutes for conditioning prior to ASCT; off-label: 16 mg/m² IV over 15-20 minutes every 4 weeks for MM.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5 hours (range: 1.5-4.0 hours) in adults. In children, half-life is shorter (~1.4 hours). Clinically, this supports high-dose, fractionated dosing regimens (e.g., every 6 hours) to maintain therapeutic levels.
Terminal elimination half-life is approximately 75 minutes (range 40-120 minutes) in patients with normal renal function; prolonged to 180-300 minutes in renal impairment
Primarily hepatic metabolism via conjugation with glutathione, followed by renal excretion of metabolites. Less than 2% of the parent drug is excreted unchanged in urine. Fecal excretion is negligible.
Primarily renal: approximately 10-30% of unchanged drug excreted in urine within 24 hours; extensive hepatic metabolism; fecal excretion accounts for <5%
Category C
Category C
Alkylating Agent
Alkylating Agent